Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
C. Rogers MD
Closed to Accrual
To estimate the rates of progression-free survival (PFS) at 3 years in each of the patient risk groups.
Data for this trial is being collected via the NRG/RTOG Data Center.
Histopathologically confirmed meningioma, confirmed by central pathology review prior to STEP 2 registration. Risk categories are defined as follows:
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.